Rockefeller Capital Management
RLAY icon

Rockefeller Capital Management’s Relay Therapeutics RLAY Stock Holding History

Rockefeller Capital Management’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.4K Buy
2,264
+1
+0% +$15 ﹤0.01% 3442
2026
Q1 		$22.5K Buy
2,263
+1,809
+398% +$16.2K ﹤0.01% 3666
2025
Q4 		$3.84K Buy
+454
New +$3.24K ﹤0.01% 4147
2023
Q1 		– Sell
-278
Closed -$4K – 3500
2022
Q4 		$4K Buy
+278
New +$5.32K ﹤0.01% 3400
2022
Q3 		– Sell
-1
Closed – – 4301
2022
Q2 		$0 Buy
+1
New +$21 ﹤0.01% 4345
2021
Q2 		– Sell
-2,166
Closed -$74K – 3576
2021
Q1 		$74K Buy
+2,166
New +$94K ﹤0.01% 1744

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Rockefeller Capital Management's RLAY Position: Q2 2026 in Review

Rockefeller Capital Management increased its Relay Therapeutics (RLAY) stake by 0.04% in Q2 2026, buying an estimated $15 and bringing the position to 2,264 shares worth $42.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3442.

Rockefeller Capital Management first reported a position in RLAY in Q1 2021 and has held it in 6 quarters since. The position peaked at $74K in Q1 2021. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Rockefeller Capital Management held 2,264 shares of Relay Therapeutics worth $42.4K as of Q2 2026.
  • Rockefeller Capital Management bought 1 Relay Therapeutics share in Q2 2026, an estimated $15.
  • Relay Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #3442 holding.
  • Rockefeller Capital Management first reported a position in Relay Therapeutics in Q1 2021 and has held it in 6 quarters since.
  • Rockefeller Capital Management's Relay Therapeutics position peaked at $74K in Q1 2021.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.